Brief: HedgePath says FDA grants orphan drug designation to its pill
02/06/2016 14:00
June 2 (Reuters) - HedgePath Pharmaceuticals Inc HPPI.PK :
* FDA grants orphan drug designation to SUBA-Itraconazole
for treatment of patients with Basal Cell Carcinoma Nevus
Syndrome (BCCNS)
Source text for Eikon: urn:newsml:reuters.com:*:nPn7FvQha
Further company coverage: HPPI.PK
(Bengaluru Newsroom: +1-646-223-8780)
Recent news on Inhibitor Therapeutics
See all newsBrief: Inhibitor Therapeutics Receives Prostate Cancer IND Clearance From FDA
Brief: Hedgepath Pharmaceuticals Provides Corporate Update For The Fourth Quarter And Year End 2018
Brief: Hedgepath Pharmaceuticals, Mayne Pharma Enter Updated Collaboration & Funding Agreements
Brief: HedgePath says FDA grants orphan drug designation to its pill